A8
A8D.F AB Science S.A
- Market cap
- EUR 51.6M
- P/E
- -
- P/B
- 15.29x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is A8D.F undervalued?
Graham numberThe Graham number of AB Science S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AB Science S.A fundamental analysis
No fundamental analysis for AB Science S.A yet.
AB Science S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's …
Full company profileAB Science S.A financial statements
AB Science S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.51M | 1.74M | 1.70M | 1.57M | 1.58M | 1.61M | 958K | 970K | 1.07M | 1.17M |
| Gross Profit | 1.06M | 1.62M | 1.45M | 1.39M | 1.51M | 1.50M | 927K | 587K | 1.25M | 978K |
| Operating Income | -30.2M | -28.4M | -28.9M | -17.5M | -14.7M | -13.8M | -15.9M | -13.4M | -6.08M | 639K |
| EBITDA | - | -26.8M | -25.1M | -20.7M | -13.8M | -11.4M | -11.6M | -7.18M | -4.92M | 1.67M |
| Net Income | -27.7M | -27.1M | -26.1M | -21.7M | -15.0M | -14.2M | -13.6M | -12.0M | -7.83M | -1.56M |
| EPS | - | -0.66 | -0.64 | -0.50 | -0.33 | -0.30 | -0.29 | -0.23 | -0.12 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 38.0M | 50.6M | 22.5M | 17.7M | 29.7M | 21.3M | 23.8M | 25.5M | 23.2M | 24.5M |
| Total Liabilities | 42.7M | 39.9M | 37.5M | 44.6M | 49.2M | 44.5M | 59.5M | 46.5M | 46.9M | 41.7M |
| Shareholders' Equity | -4.71M | 10.7M | -15.0M | -26.8M | -19.5M | -23.2M | -35.7M | -21.0M | -23.8M | -17.2M |
| Cash & Short-term Investments | 19.8M | 38.8M | 11.6M | 5.70M | 20.7M | 8.72M | 7.27M | 6.07M | 7.99M | 10.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -33.5M | -22.9M | -26.8M | -15.2M | -13.5M | -17.2M | -17.5M | -16.9M | 525K | -4.29M |
| Capital Expenditure | 524K | 503K | 484K | 390K | 370K | 564K | 644K | 345K | 155K | 282K |
| Free Cash Flow | - | -23.4M | -27.3M | -15.5M | -13.9M | -17.7M | -18.1M | -17.2M | 370K | -4.57M |
| Ratios | ||||||||||
| ROE | - | -252.7% | - | - | - | - | - | - | - | - |
| ROA | -72.9% | -53.6% | -115.9% | -122.6% | -50.7% | -66.7% | -57.1% | -47.0% | -33.8% | -6.3% |
| Net Profit Margin | -1,836.6% | -1,559.6% | -1,532.1% | -1,384.3% | -950.4% | -882.9% | -1,421.2% | -1,235.6% | -730.5% | -132.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AB Science S.A dividends
AB Science S.A has not paid dividends in the last 10 fiscal years.
Who owns AB Science S.A
- Insiders 47.71%
- Institutions 0.00%
- Public & others 52.29%
- Shares outstanding 96.5M
- Free float 19.0M
AB Science S.A company profile
- Company name
- AB Science S.A
- Ticker
- A8D.F
- ISIN
- FR0010557264
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 33
- Fiscal year end
- December
- Address
- 3, Avenue George V, Paris, France, 75008
- Phone
- 33 1 47 20 00 14
- Website
- ab-science.com
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
AB Science S.A management
8- Prof. Christian Auclair M.D., Ph.D.Deputy MD & Director
- Mr. Stéphane C. LedermannCEO & Director
- Mr. Laurent Guy MBAChief Financial Officer
- Mr. Denis GicquelExecutive Vice-President
- Mr. Christian FASSOTTEGlobal Chief Medical Officer
- Mr. Alexis BERNARDHead of Veterinary Sales
- Mr. Harshad KULKARNIHead of Statistics
- Dr. Albert Ahn D.V.M.President of USA Operations